Article Sidebar

PDF
Date Published: 28/12/2024
Abstract Views: 0
Views PDF: 0
DOI: https://doi.org/10.56535/jmpm.v49i9.981
Issue
Vol. 49 No. 9 (2024): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ SỐ 9 - 2024
Section
Articles
How to Cite
Dinh Viet, D., Bui Dang, T. A., Chu, V. M., Hoang, X. S., Dinh Pham, H. D., & Pham, N. H. (2024). PROTECTIVE EFFICACY OF NANOCOVAX VACCINE DOSE 25µg AGAINST COVID-19 IN VIETNAMESE VOLUNTEERS. Journal of Military Pharmaco-medicine, 49(9), 69-79. https://doi.org/10.56535/jmpm.v49i9.981

PROTECTIVE EFFICACY OF NANOCOVAX VACCINE DOSE 25µg AGAINST COVID-19 IN VIETNAMESE VOLUNTEERS

Dinh Viet Duc1, Bui Dang The Anh1, Chu Van Men2, Hoang Xuan Su2, Dinh Pham Hoang Duong3, Pham Ngoc Hung1,
1 Học viện Quân y
2 Viện Nghiên cứu Y Dược học Quân sự, Học viện Quân y
3 Trung tâm kiểm soát bệnh tật tỉnh Hưng Yên

Main Article Content

Abstract

Objectives: Evaluating the protective efficacy of Nanocovax vaccine dose 25µg against COVID-19 in Vietnamese volunteers aged 18 years and older. Methods: Phases 2 and 3 randomized-control doubled-blinded clinical trial studies were conducted on healthy volunteers aged 18 years and older who received either the study vaccine or a placebo according to a 2-dose regimen, 28 days apart, to evaluate the protective efficacy of Nanocovax vaccine against Covid-19 infection. Result: Efficacy against clinically symptomatic COVID-19 of any severity approximately two months after the second vaccination was 89.63% (51.97 - 97.76) and gradually decreased over time. The vaccine effectively prevents moderate progression of COVID-19 disease, death, and mortality, reaching 93.22% (70.16 - 98.46); Prevention of severe progression and death reached 95.67% (66.48 - 99.44). Conclusion: Nanocovax vaccine with a dose of 25µg effectively protects against severe progression of COVID-19 in volunteers.

Article Details

Keywords

Vaccine Efficacy, COVID-19, Nanocovax

References

1. Zhu N, Zhang D, Wang W, et al. (2020). A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733.
2. Kaur SP and Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020; 288:198114.
3. Orenstein WA, Bernier RH, Dondero TJ, et al. Field evaluation of vaccine efficacy. Bull World Health Organ. 1985; 63(6):1055-1068.
4. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615.
5. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; DOI: NEJMoa2035389.
6. Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at completion of the placebo-controlled phase of a randomized controlled trial. Clin Infect Dis Off Publ Infect Dis Soc Am. 2022; 76(3):398-407.
7. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single0blind, randomised controlled trial. Lancet Lond Engl. 2020; 396(10249):467-478.
8. Research C for BE. Development and licensure of vaccines to prevent COVID-19. 2023 .
9. WHO. WHO target product profiles for COVID-19 Vaccines. Revised version April 2022. .
10. Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet Lond Engl. 2021; 398(10317):2173-2184.